Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases

CONCLUSION: Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.PMID:37916138 | PMC:PMC10507213 | DOI:10.2174/18743064-v17-e230714-2022-26
Source: Open Respiratory Medicine Journal - Category: Respiratory Medicine Authors: Source Type: research